Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Kyowa Kirin Pharmaceutical Development Ltd.

Home Clinical Trial Sponsors and OrganizationsKyowa Kirin Pharmaceutical Development Ltd.

Kyowa Kirin Pharmaceutical Development Ltd.

ACTIVE

United Kingdomwww.kyowakirin.comSubsidiary

Part of KYOWA KIRIN INTERNATIONAL PLC

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

23

10 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

15

65.2%

Phase 3

1

4.3%

Trial Status Distribution

Active, not recruiting

10

43.5%

Completed

9

39.1%

Recruiting

1

4.3%

Terminated

1

4.3%

Withdrawn

2

8.7%

Clinical Trials

Trials sponsored by this organization (23)

Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER)

Nov 202273 participants

A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth

Nov 202125 participants

A UK Multicentre, Health-Related Quality of Life Study for Children and Adolescents With XLH

Apr 202132 participants

Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age

Feb 202016 participants

A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients from Birth to Less than 1 Year of Age with X-linked Hypophosphatemia (XLH)

Active, not recruiting

Nov 201920 participants

A Phase 1/2, Study to measure the safety, tolerability and the action of drugs in the body (method and rate of excretion; duration of effect on the body) and effectivity of Burosumab in children from birth to less than 1 year of age with inheritable form of rickets

Active, not recruiting

Oct 201920 participants

A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients from Birth to Less than 1 Year of Age with X-linked Hypophosphatemia (XLH)

Active, not recruiting

Oct 201920 participants

A Phase 1/2, Study to measure the safety, tolerability and the action of drugs in the body (method and rate of excretion; duration of effect on the body) and effectivity of Burosumab in children from birth to less than 1 year of age with inheritable form of rickets

Active, not recruiting

Oct 201920 participants

Page 1 of 3

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials23
Approvals
News

Back to Organizations